LB Pharmaceuticals Inc Operating Cash Flow
LB Pharmaceuticals Inc (LBRX) reported Operating Cash Flow of -$60.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$37.63M.
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$23.29M.
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.10M.
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.37M.
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2025 was -$35.21M.
- LB Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2024 was -$53.05M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$37.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$60.92M 10-Q · filed 2026-08-11 | -$79.02M derived: sum of 3 quarters · filed 2026-08-11 | -$82.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$23.29M 10-Q · filed 2026-05-12 | -$41.39M derived: sum of 2 quarters · filed 2026-05-12 | -$44.77M derived: sum of 3 quarters · filed 2026-05-12 | -$50.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$18.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$21.48M derived: sum of 2 quarters · filed 2026-03-26 | -$27.08M derived: sum of 3 quarters · filed 2026-08-11 | -$35.21M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$3.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.98M derived: sum of 2 quarters · filed 2026-08-11 | -$17.11M 10-Q · filed 2025-11-06 | -$22.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$13.73M 10-Q · filed 2026-08-11 | -$19.40M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$8.13M 10-Q · filed 2026-05-12 | -$13.79M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2024-12-31 | -$5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$53.05M 10-K · filed 2026-03-26 | ||
| 2024-09-30 | -$47.39M 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |